C Michael Gibson/Baim Institute
Feb 16, 2026, 06:21
C. Michael Gibson: Favorable Safety Outcomes With Asundexian
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, and Executive Board Member at EXCITE International, shared a post on LinkedIn:
”No increase in any type of bleeding with Asundexian. Even minor bleeding was not increased (was numerically lower).”
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration